
KYTX Stock Forecast & Price Target
KYTX Analyst Ratings
Bulls say
Kyverna Therapeutics Inc. is experiencing an increased confidence in its product candidate, KYV-101, particularly in the treatment of Myasthenia Gravis (MG), with a raised probability of approval from 25% to 35%, reflecting strong clinical data on durability and response times in patients. Additionally, the company has demonstrated promising results for KYV-101 across multiple autoimmune conditions, including rheumatoid arthritis (RA), where data suggests its efficacy surpasses existing therapies like rituximab. Overall, the augmenting clinical evidence and growing recognition of KYV-101's capabilities in various indications contribute positively to its long-term financial outlook and market potential.
Bears say
Kyverna Therapeutics faces significant challenges that raise concerns about its financial outlook, primarily due to the lack of durable responses observed in patients treated with its lead product candidate, KYV-101, particularly in lupus nephritis (LN) and myasthenia gravis (MG). Additionally, the potential failure to generate favorable data for KYV-101 in secondary progressive multiple sclerosis (SPS) further compounds the uncertainties surrounding its product pipeline. Lastly, the prospect of long-term dilution risk presents further financial instability, which could negatively impact shareholder value and investor confidence.
This aggregate rating is based on analysts' research of Kyverna Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
KYTX Analyst Forecast & Price Prediction
Start investing in KYTX
Order type
Buy in
Order amount
Est. shares
0 shares